MorphoSys AG (MOR)
NASDAQ: MOR · IEX Real-Time Price · USD
17.51
+0.10 (0.57%)
May 1, 2024, 4:30 PM EDT - Market closed
MorphoSys AG Revenue
In the year 2023, MorphoSys AG had annual revenue of $264.75M, a decrease of -10.56%.
Revenue (ttm)
$264.75M
Revenue Growth
+6.07%
P/S Ratio
9.96
Revenue / Employee
$505,255
Employees
524
Market Cap
2.64B USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 264.75M | -31.28M | -10.56% |
Dec 31, 2022 | 296.03M | 91.92M | 45.04% |
Dec 31, 2021 | 204.10M | -195.53M | -48.93% |
Dec 31, 2020 | 399.63M | 319.01M | 395.67% |
Dec 31, 2019 | 80.62M | -7.24M | -8.24% |
Dec 31, 2018 | 87.86M | 7.71M | 9.62% |
Dec 31, 2017 | 80.15M | 27.80M | 53.11% |
Dec 31, 2016 | 52.35M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
QuidelOrtho | 3.00B |
Premier | 1.32B |
Neogen | 929.24M |
PTC Therapeutics | 927.56M |
PROCEPT BioRobotics | 136.19M |
Arcellx | 110.32M |
Merus | 43.95M |
Celldex Therapeutics | 6.88M |
MOR News
- 2 days ago - MorphoSys AG Reports First Quarter 2024 Financial Results - Business Wire
- 2 days ago - Morphosys says Novartis takeover progressing as planned for H1 2024 - Reuters
- 7 days ago - MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting - Accesswire
- 20 days ago - MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis - Accesswire
- 20 days ago - Novartis begins tender offer for MorphoSys - Reuters
- 20 days ago - Novartis tender offer for MorphoSys AG commences - GlobeNewsWire
- 5 weeks ago - MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act - Accesswire
- 7 weeks ago - MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - Business Wire